Mattia Calissano

Mattia Calissano is a seasoned professional in pharmacovigilance and drug safety, currently serving as Head of Pharmacovigilance at Orchard Therapeutics since September 2019. Responsibilities encompass leading safety strategies for both developmental and post-marketing products, including the preparation of regulatory submission packages and implementation of robust pharmacovigilance systems. Prior experience includes roles as Head of Drug Safety and Risk Management and Medical Assessor at the Medicines and Healthcare Products Regulatory Agency, focusing on benefit-risk assessment and safety signal presentation. Earlier career roles involved clinical research positions at prestigious institutions, where contributions included leading international collaborations on Duchenne muscular dystrophy research and conducting phase II clinical trials for novel therapies. Educational qualifications include a Master's degree in Clinical Pharmacology from King's College London, a PhD in Neuroscience from UCL, and a medical degree from Università La Sapienza in Rome, Italy.